Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics' Chief R&D Officer Jonathan Zalevsky reported a small share sale primarily for tax purposes. On May 19, 2026, he sold 199 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations linked to vesting restricted stock units. The filing states this did not represent a discretionary trade. Following the transaction, he directly held 20,975 shares of Nektar Therapeutics common stock.
Nektar Therapeutics President & CEO Howard W. Robin reported a small tax-related share sale. On this Form 4, he sold 444 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations from vesting RSUs, which the company notes was not a discretionary trade.
After the sale, Robin directly holds 75,045 shares of Nektar common stock and has an additional 28 shares reported as indirectly owned through his spouse. The filing reflects routine equity compensation and related tax settlement rather than a change in his overall investment stance.
Biotechnology Value Fund and affiliated reporting persons amended a Schedule 13G to report beneficial ownership in Nektar Therapeutics common stock. As of the close of business on March 31, 2026, the Reporting Persons report holding an aggregate of specified positions, including 1,523,980 shares beneficially owned by BVF and 1,114,072 shares beneficially owned by BVF2. The filing states a denominator of 28,687,963 Shares outstanding as of March 11, 2026 used to compute percentages, and discloses 293,103 shares issuable upon exercise of Pre-Funded Warrants held by the Reporting Persons.
Nektar Therapeutics filed a prospectus supplement to offer up to $150,000,000 of common stock through an Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC, enabling at-the-market sales from time to time. The sales agents will be paid a 3.0% commission and settlement is generally one business day after each sale.
The prospectus states an illustrative sale of 1,762,839 shares at an assumed price of $85.09 (last reported sale price on May 6, 2026), and discloses 33,786,032 shares outstanding as of April 30, 2026. Net proceeds are for general corporate purposes, including R&D and clinical development (notably Phase 3 trials for rezpegaldesleukin).
Nektar Therapeutics entered into an Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright, allowing at-the-market offerings of up to $150,000,000 of common stock under its automatic shelf registration. The agents will receive a 3.0% commission on gross sales and customary indemnification and expense reimbursement.
The company also announced that interim Chief Financial Officer Sandra Gardiner will retire and step down effective May 15, 2026. FLG Partners’ Linda Rubinstein will become interim Chief Financial Officer and principal financial and accounting officer under an amended consulting agreement with FLG at $650 per hour, terminable on 15 days’ notice.
Nektar Therapeutics reported a first-quarter 2026 net loss of $44.9 million on total revenue of $10.9 million, all from non-cash royalty revenue tied to previously sold royalty streams. Operating expenses were $49.9 million, driven mainly by research and development spending.
The company’s cash and investments in marketable securities rose sharply to $731.6 million as of March 31, 2026, supported by recent equity offerings and at-the-market sales that generated net proceeds of $1.07 billion between July 2025 and April 2026. Shares of common stock outstanding were 33,786,032 on May 1, 2026.
Nektar Therapeutics reported first quarter 2026 results showing a smaller loss and a much stronger balance sheet. Revenue was $10.9 million, slightly above $10.5 million a year ago, primarily from non-cash royalty revenue.
Net loss narrowed to $44.9 million, or $1.82 per share, compared with a $50.9 million loss, or $3.62 per share, in the first quarter of 2025. Research and development spending rose to $35.7 million as the company prepared a Phase 3 program for rezpegaldesleukin in atopic dermatitis, while general and administrative costs fell to $13.4 million mainly from lower legal expenses.
Cash and investments in marketable securities totaled $731.6 million at March 31, 2026, up from $245.8 million at December 31, 2025, and exclude approximately $351 million of net proceeds from a secondary offering completed on April 23, 2026. Management highlighted plans to initiate the Phase 3 ZENITH-AD program by July and to hold an End-of-Phase 2 meeting for alopecia areata this quarter.
FMR LLC reports beneficial ownership of 4,303,188.37 shares of Nektar Therapeutics common stock, representing 15.0% of the class as of 03/31/2026. The filing lists related interests held by Fidelity Growth Company Fund (5.6%, 1,608,001 shares) and Fidelity Growth Company Commingled Pool (6.5%, 1,861,842 shares) as of 03/31/2026. The schedule is filed under an amendment and is signed by an authorized representative pursuant to a Power of Attorney.